Postby Surroundedbylove » Wed May 25, 2011 6:47 am
With the switch from 5FU to Xeloda you need to be sure to calculate weeks, not cycles because the cycles are different on Xeloda (3 week cycles instead of 2 week cycles).
For example - 4 cycles of Xeloda equals 12 weeks which equals 6 cycles of 5FU. Also a "month" means exactly 4 weeks. So, you shouldn't look at total number of cycles since you're mixing FOLFOX and XELOX protocols. I had one cycle of FOLFOX and the remaining of XELOX but even in XELOX I did it differently (see below). After subtracting true chemo breaks (not just the one week off that is normal during a cycle) my onc has a total number of weeks goal.
So - to go back to your original question - I do see that there seem to be some regional differences but they may also be differences based on prognostic factors and we don't all talk about those in detail on here when comparing things. My onc's goals for a patient with reasonably good prognostic factors who is stage 3 is for the patient to have 5 months of treatment (20 weeks) minimum with the extra month or month and a half (4 to 6 weeks) as "icing on the cake." He frequently drops the oxaliplatin during the last month to month and a half and also frequently drops the dosage of the 5FU or Xeloda during that last month to month and a half. He claims that the studies show that in most cases the shorter course is just as effective.
For rectal cancer the 6 weeks of chemo during radiation, if given at normal dosages (which he does - and he includes oxaliplatin too) counts toward these weeks - but you count it a little differently because there aren't chemo breaks - the 6 weeks counts as 8 weeks (as if you had the 2 one week breaks).
Also - I was having a hard time with the oxaliplatin during my adjuvant chemo. I ended up getting lower dose weekly infusions - it greatly helped me to manage side effects and yet still get the total amount of oxaliplatin recommended. If your mom wants to explore that option, it isn't something the onc would likely bring up. She should discuss it with him/her.
I hope this helps.
Edited to add a little information
Surroundedbylove
Rectal Cancer @ 43, '08
Clinical: T3,N2a,MX (IIIB)
6 wks XELOX & radiation
LAR, colonic j-pouch, & temp ileo '09
Surgical: ypT3,ypN0,ypMX (0 of 20 nodes)
FOLFOX; XELOX
Ileo Takedown ‘09
LARS for 10 years before learning it is finally being studied
InterStim Sacral Nerve Neuromodulator 2019